EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update
09 Março 2016 - 9:46PM
EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play
biosimilar company focused on the development and commercialization
of biosimilar monoclonal antibodies (mAbs), today announced it will
release its fourth quarter and fiscal year 2015 financial results
on Tuesday, March 15, 2016. In conjunction with the release,
the Company has scheduled a conference call and webcast on Tuesday,
March 15, 2016 at 8:00 a.m. ET to discuss the financial results and
provide a business update.
Conference Call InformationWhen:
Tuesday, March 15, 2016, 8:00 a.m. ETDial-in: 1-855-638-3957
(United States) or 1-224-633-1318 (International)Conference ID:
58250825Webcast: http://ir.epirusbiopharma.com/events.cfmPlease
join the conference call at least 10 minutes early to register. The
webcast will be archived on EPIRUS' website for a period of three
months.
About EPIRUS
BiopharmaceuticalsEPIRUS
Biopharmaceuticals (Nasdaq:EPRS) is a pure-play biosimilar
company focused on the global development and commercialization of
biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve
global patient access to important, cost-effective medicines. The
company’s current pipeline of biosimilar product candidates
includes: BOW015 (infliximab, reference biologic
Remicade®), currently marketed outside the U.S. and in an ongoing
global Phase 3 study for registration in Europe and North
America; BOW050 (adalimumab, reference biologic
Humira®); BOW070 (tocilizumab, reference biologic
Actemra®); BOW080 (eculizumab, reference biologic
Soliris®); BOW090 (ustekinumab, reference biologic
STELARA®); and BOW100 (golimumab, reference biologic
SIMPONI®)i. The reference products for these candidates together
generated approximately $29.2 billion in global sales for
2014, according to EvaluatePharma®. EPIRUS has established multiple
partnerships to support its regulatory and commercialization
efforts in global markets.
i. Remicade is a registered trademark of Johnson
and Johnson; Humira is a registered trademark of AbbVie; Actemra is
a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a
member of the Roche Group; Stelara is owned and marketed by
Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson
and Johnson; Simponi is marketed by Janssen Biotech Inc; Soliris is
a registered trademark of Alexion Pharmaceuticals, Inc.
Contact Information
For investor inquiries:
Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals
+1-617-553-9716
mciszewski@epirusbiopharma.com
For media inquiries:
Hope Buggey, FleishmanHillard
+1-919-336-3786
hope.buggey@fleishman.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre EPIRUS Biopharmaceuticals Inc (CE) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de